Understanding Your Cancer Treatment Options: The PD-L1 22C3 Test
When facing a cancer diagnosis, having clear information about your treatment options can bring much-needed peace of mind. The PD-L1 22C3 Immunohistochemistry test is a specialized diagnostic tool that helps determine if immunotherapy might be an effective treatment approach for your specific cancer type. At Oracle Genomics, we understand the anxiety that comes with cancer testing, which is why we provide accurate, reliable results with the compassion and professionalism you deserve.
What the PD-L1 22C3 Test Detects
This advanced test measures the level of PD-L1 protein expression in your tumor tissue. PD-L1 is a protein that some cancer cells use to “hide” from your immune system. When this protein is present at high levels, it suggests that your cancer might respond well to immunotherapy drugs called checkpoint inhibitors. These medications work by blocking the PD-L1 pathway, allowing your immune system to recognize and attack cancer cells more effectively.
Who Should Consider This Test
This test is particularly important for patients with:
- Non-small cell lung cancer (NSCLC)
- Head and neck cancers
- Bladder cancer
- Melanoma
- Other solid tumors being considered for immunotherapy
If your oncologist is exploring immunotherapy as a treatment option, this test provides the critical information needed to make an informed decision about whether these advanced treatments might benefit you.
Why This Test Matters for Your Health Journey
Getting accurate PD-L1 testing can significantly impact your treatment outcomes by:
- Personalizing your treatment: Helps determine if immunotherapy is likely to work for your specific cancer
- Avoiding unnecessary treatments: Prevents pursuing therapies that may not be effective for your cancer type
- Maximizing treatment success: Increases the likelihood of positive response to chosen therapies
- Providing peace of mind: Gives you and your family clarity about available treatment options
Understanding Your Test Results
Your results will indicate the percentage of tumor cells expressing PD-L1. Higher percentages generally suggest better potential response to immunotherapy. Our expert team provides clear, easy-to-understand reports that your oncologist will discuss with you, explaining what the results mean for your specific situation and treatment plan.
Remember: A positive PD-L1 result doesn’t guarantee treatment success, and a negative result doesn’t mean immunotherapy won’t work—it’s one piece of information your medical team uses to create your comprehensive treatment strategy.
Transparent Pricing for Peace of Mind
| Test Option | Price | Turnaround Time |
|---|---|---|
| Regular Price | R6,100 | 5-7 days |
| Special Price | R5,500 | 5-7 days |
Considering the potential impact on your treatment decisions and quality of life, this test represents excellent value in your cancer care journey.
Why Trust Oracle Genomics
- Nationwide Coverage: Accessible testing services across South Africa, including Johannesburg, Cape Town, Durban, and Pretoria
- Expert Methodology: Advanced immunohistochemistry techniques ensuring accurate, reliable results
- Fast Turnaround: Results typically available within 5-7 days for timely treatment decisions
- Professional Expertise: Working closely with oncologists and healthcare providers nationwide
- Patient-Focused Care: Understanding the emotional journey of cancer testing and treatment
Take the Next Step in Your Cancer Care
Don’t delay this important testing that could open doors to effective treatment options. With our special pricing of R5,500, now is the time to get the clarity you need.
Required for Testing: Please provide a copy of your histopathology report, biopsy site information, and clinical history with your sample.
Early testing can lead to earlier treatment decisions and better outcomes. Contact us today to schedule your PD-L1 22C3 test.
